Positive Phase 1b Results for I-Mab's Givastomig in Metastatic Gastric Cancer Show 71% Objective Response Rate with Favorable Safety Profile

I-Mab reported positive Phase 1b study results for givastomig, a bispecific antibody, in metastatic gastric cancers, demonstrating a 71% objective response rate (ORR) across all dose levels, and an 83% ORR at selected expansion doses, with a favorable safety profile. This combination therapy with nivolumab and chemotherapy addresses a significant unmet medical need, though the small cohort size (17 patients) in this early-stage trial necessitates further validation. The company plans to present updated data at the ESMO GI Congress on July 2nd and host a virtual investor event on July 8th.

Analysis

I-Mab's Phase 1b trial results for givastomig present a compelling, yet high-risk, clinical profile. The bispecific antibody demonstrated significant efficacy in first-line metastatic gastric cancer, with a 71% objective response rate (ORR) across all doses and an impressive 83% ORR at the two dose levels selected for expansion. Critically, these responses were observed even in patient populations with low CLDN18.2 and PD-L1 expression, potentially broadening the drug's addressable market. The favorable safety profile, marked by a low incidence of severe toxicities and no dose-limiting toxicities, is a key differentiator for a 4-1BB targeting agent. However, these strong results are based on a very small cohort of 17 patients, making them preliminary and subject to validation in larger studies. Contrasting with this positive clinical news is the significant institutional selling pressure observed in recent quarters. Major holders, including Morgan Stanley and Caligan Partners, have almost completely liquidated their positions, suggesting a lack of conviction or a strategic exit that predates this data release. This divergence between promising early data and negative institutional flows creates a conflicted investment picture, with upcoming catalysts like the ESMO GI presentation on July 2nd and the investor event on July 8th being crucial for further validation.

Key Decisions for Investors

• Investors should weigh the highly promising early-stage clinical data against the notable divestment from large institutional holders, recognizing this as a high-risk, high-reward scenario pending further de-risking.
• Closely monitor the upcoming ESMO GI presentation on July 2nd and the subsequent investor call on July 8th for updated data, particularly on response durability and subgroup analysis, which will be critical near-term catalysts.
• Given the small trial size and conflicting institutional signals, any position should be considered speculative; potential investors should size positions accordingly, while current holders might evaluate the risk-reward profile in light of the heavy institutional selling.